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Multiple sclerosis-associated CLEC16A controls
HLA class II expression via late endosome
biogenesis
Marvin M. van Luijn,1,* Karim L. Kreft,2,* Marlieke L. Jongsma,3 Steven W. Mes,1
Annet F. Wierenga-Wolf,1 Marjan van Meurs,1 Marie-Jose´ Melief,1 Rik van der Kant,3
Lennert Janssen,3 Hans Janssen,3 Rusung Tan,4,5 John J. Priatel,5 Jacques Neefjes,3
Jon D. Laman1,† and Rogier Q. Hintzen2,†
*,† These authors contributed equally to this work.
C-type lectins are key players in immune regulation by driving distinct functions of antigen-presenting cells. The C-type lectin
CLEC16A gene is located at 16p13, a susceptibility locus for several autoimmune diseases, including multiple sclerosis. However,
the function of this gene and its potential contribution to these diseases in humans are poorly understood. In this study, we found a
strong upregulation of CLEC16A expression in the white matter of multiple sclerosis patients (n = 14) compared to non-demented
controls (n = 11), mainly in perivascular leukocyte inﬁltrates. Moreover, CLEC16A levels were signiﬁcantly enhanced in peripheral
blood mononuclear cells of multiple sclerosis patients (n = 69) versus healthy controls (n = 46). In peripheral blood mononuclear
cells, CLEC16A was most abundant in monocyte-derived dendritic cells, in which it strongly co-localized with human leukocyte
antigen class II. Treatment of these professional antigen-presenting cells with vitamin D, a key protective environmental factor in
multiple sclerosis, downmodulated CLEC16A in parallel with human leukocyte antigen class II. Knockdown of CLEC16A in
distinct types of model and primary antigen-presenting cells resulted in severely impaired cytoplasmic distribution and formation of
human leucocyte antigen class II-positive late endosomes, as determined by immunoﬂuorescence and electron microscopy.
Mechanistically, CLEC16A participated in the molecular machinery of human leukocyte antigen class II-positive late endosome
formation and trafﬁcking to perinuclear regions, involving the dynein motor complex. By performing co-immunoprecipitations, we
found that CLEC16A directly binds to two critical members of this complex, RILP and the HOPS complex. CLEC16A silencing in
antigen-presenting cells disturbed RILP-mediated recruitment of human leukocyte antigen class II-positive late endosomes to peri-
nuclear regions. Together, we identify CLEC16A as a pivotal gene in multiple sclerosis that serves as a direct regulator of the
human leukocyte antigen class II pathway in antigen-presenting cells. These ﬁndings are a ﬁrst step in coupling multiple sclerosis-
associated genes to the regulation of the strongest genetic factor in multiple sclerosis, human leukocyte antigen class II.
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Introduction
Recent genome-wide association studies demonstrate that
single nucleotide polymorphisms at the 16p13 locus con-
taining C-type lectin domain family 16, member A
(CLEC16A) increase the risk of developing multiple scler-
osis (Haﬂer et al., 2007; Hoppenbrouwers et al., 2009;
Sawcer et al., 2011; Beecham et al., 2013). This risk
locus is also associated with several other autoimmune dis-
eases, such as type I diabetes (Hakonarson et al., 2007),
primary biliary cirrhosis (Mells et al., 2011) and coeliac
disease (Dubois et al., 2010). Hence, CLEC16A likely
plays a key role in the pathogenesis of autoimmune dis-
eases, but its biological function in humans is completely
unknown.
CLEC16A is a family member of the C-type lectins,
which are broadly expressed by antigen-presenting cells
and share innate immune functions in recognition of patho-
gens or (altered) self molecules via their carbohydrate rec-
ognition domains (Geijtenbeek et al., 2004; Geijtenbeek
and Gringhuis, 2009). Certain C-type lectins, such as DC-
SIGN (now known as CD209), DEC-205 (now known as
LY75) and Dectin-1 (now knwon as CLEC7A), contain
speciﬁc internalization motifs to target antigens into the
endosomal pathway required for human leukocyte antigen
class II (HLA-II)-mediated antigen presentation to T cells
(Geijtenbeek et al., 2004). However, the short carbohydrate
recognition domain of CLEC16A is predicted to be inactive
(Zelensky and Gready, 2005; Todd et al., 2007), suggesting
a non-classical C-type lectin function.
The CLEC16A gene is associated with a set of other
immune genes located on the short arm of chromosome
16, which is considered to be an important locus in the
pathogenesis of multiple sclerosis (Zuvich et al., 2011;
Berge et al., 2013). CLEC16A is localized adjacent to
CIITA, the master transcription factor of HLA-II (Choi
et al., 2011). HLA-II is long established as the strongest
genetic risk factor in multiple sclerosis, but its role in mul-
tiple sclerosis pathogenesis is still unclear (Ramagopalan
et al., 2009a). There is growing interest in proteins serving
as direct regulators of the HLA-II antigen presentation
pathway and revealing linkage to autoimmune disease
(Paul et al., 2011).
In Drosophila, the human CLEC16A orthologue Ema
has been identiﬁed as a protein directly involved in endo-
somal maturation (Kim et al., 2010). The formation of
late endosomal compartments is an important step in the
HLA-II antigen presentation pathway. HLA-II molecules
synthesized in the endoplasmic reticulum are transported
to specialized mature late endosomes called MIIC (MHC
class II-containing compartment) (Neefjes et al., 1990;
Peters et al., 1995). In these MIIC, HLA-II molecules are
loaded with peptides for presentation at the plasma mem-
brane. Therefore, we hypothesize that CLEC16A plays a
key role in this process.
Here, we demonstrate that CLEC16A expression directly
links to multiple sclerosis and controls the HLA-II antigen
presentation pathway via late endosomal maturation.
CLEC16A levels were strongly elevated in multiple sclerosis
patients compared to control subjects. CLEC16A knock-
down in various antigen-presenting cells showed that
CLEC16A is a key regulator of late endosomal biogenesis
to drive HLA-II expression, a novel function for C-type lec-
tins. Based on these ﬁndings, we propose that CLEC16A
promotes late endosomal maturation to disrupt the HLA-II
antigen presentation pathway in multiple sclerosis.
Materials and methods
Clinical samples
Multiple sclerosis patients were between 18 and 65 years of
age and diagnosed according to the McDonald criteria
(Polman et al., 2005). Gender-matched healthy control subjects
were aged between 18 and 55 years and were relatives or
family members of patients included in this study. Exclusion
criteria were prior symptoms suggestive of or diagnosis with
multiple sclerosis as well as the use of immunomodulatory
agents for other autoimmune diseases. All patients and con-
trols gave written informed consent. Post-mortem brain tissue
of patients with multiple sclerosis and non-demented control
subjects was obtained from the Netherlands Brain Bank (NBB;
Amsterdam, The Netherlands). Samples and clinical informa-
tion was collected from donors who gave written informed
consent for brain autopsy. Cryopreserved brain tissues were
stored at 80C until use. This study was approved by the
Medical Ethical Committee of the Erasmus MC, University
Medical Center.
Human cell cultures
The melanoma cell line MelJuSo was cultured in Iscove’s mod-
iﬁed Dulbecco’s medium (IMDM) (Lonza) supplemented with
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8% foetal calf serum. Rab7-GFP+MelJuSo cells were gener-
ated as reported previously (Jordens et al., 2001). The
HEK293T cell line was grown in Dulbecco’s modiﬁed
Eagle’s medium (Lonza) containing 8% foetal calf serum and
1% penicillin-streptomycin. Peripheral blood samples of pa-
tients and controls were collected in Vacutainer CPT tubes
(BD Biosciences). Peripheral blood mononuclear cells from
buffy coats (Sanquin) were isolated using standard Ficoll-
Paque (Amersham Pharmacia Biotech) density-gradient centri-
fugation. A Percoll density gradient or CD14 microbeads
(Miltenyi Biotec) was used to isolate monocytes from periph-
eral blood mononuclear cell fractions, resulting in a purity of
CD14+ cells of 490% as determined by ﬂow cytometry. For
differentiation into monocyte-derived dendritic cells, the iso-
lated monocyte fraction was cultured in the presence of GM-
CSF (600U/ml; BioSource) and IL4 (400U/ml; R&D Systems).
Cells were treated with or without the active form of vitamin
D (107M) After washing and seeding, monocyte-derived den-
dritic cells were matured by lipopolysaccharide (LPS) treatment
(Sigma-Aldrich; E. coli 026:B6, 1 mg/ml) for 16 h.
Macrophages were differentiated from primary monocytes by
culturing in RPMI (Lonza) with 5% normal human serum for
5 days under non-adherent conditions using Teﬂon conical
ﬂasks.
DNA isolation and genotyping
DNA was isolated from blood pellets obtained in EDTA tubes
according to standard laboratory practice as previously re-
ported (Aulchenko et al., 2008). Multiple sclerosis risk single
nucleotide polymorphism rs7200786 in CLEC16A was as-
sessed on the Illumina 610K array or with a custom-made
Sequenom array, both according to the manufacturers’
protocols.
Production of DNA constructs
CLEC16A cDNA (GenBank no BC112897.1) was cloned into
the Bgl2-EcoR1 sites of 2HA-C1 and mGFP-C1. CLEC16A
cDNA ligation was checked using classical PCR and
CLEC16A mRNA overexpression in cells transfected with
these constructs was validated using quantitative PCR
(Supplementary Fig. 5A). GFP-, mRFP- and HA-RILP as well
as HA-VPS41 DNA constructs were produced as previously
shown (Jordens et al., 2001; van der Kant et al., 2013).
Constructs were transformed into Escherichia coli DH5 com-
petent cells, which were plated out on Luria broth agar plates
containing the appropriate antibiotics to select for single colo-
nies at 37C. A single colony was further grown overnight in
250–500ml Luria broth selection medium and plasmid DNA
was isolated using Midiprep or Maxiprep kits (Roche Applied
Science).
Silencing RNA and DNA
transfections
One day before transfection, fresh culture medium without
penicillin/streptomycin was added. For each transfection,
siGENOME silencing small interfering RNA (siRNA) duplexes
(500 nM; Thermo Fisher Scientiﬁc) were mixed with
DharmaFECT reagent in IMDM in 96 - or 24-well plates
(ﬂat bottomed). After 20min incubation at room temperature,
cells were added to the mixture and cultured for 3 days. For
immunoﬂuorescence analysis, cells were grown on cover slides
(Thermo Fisher Scientiﬁc). We used three different CLEC16A
siRNA duplexes: #1, UCACAGGUCUUCUUAAUUA; #2,
UGUCUGAGAUGUACGCUAA; and #3,
CGUAAAUUCUAUCAUCGUU. Scrambled and HLA-DMb
siRNA duplexes were used as internal controls in each experi-
ment. To exclude off-target effects, we tested the effects of
combinations of CLEC16A siRNA duplexes on both
CLEC16A and HLA-DRA mRNA expression.
To overexpress CLEC16A, rab7-interacting lysosomal pro-
tein (RILP) or homotypic fusion and vacuole protein sorting
(HOPS) complex proteins, we transfected the MelJuSo cell line
with DNA constructs using either FuGENE 6 or X-
tremeGENE 9 reagent (Roche Applied Science). In short,
DNA was mixed with transfection reagent supplemented in
serum-free IMDM and incubated for 20min at room tempera-
ture. The mixture was then added drop-wise to the cells 1 or 2
days after CLEC16A siRNA transfection. HEK293T cells were
seeded 60–70% conﬂuent. For these cells, a mixture of serum-
free Dulbecco’s modiﬁed Eagle’s medium, polyethylenimine
[1mg/ml diluted in phosphate-buffered saline (PBS)] and
DNA was added after 30min incubation at room temperature.
Cells were harvested and analysed 24–48 h after incubation.
Lentivirus production and transduc-
tion into monocytes
We obtained lentiviral pLKO.1 constructs containing speciﬁc
CLEC16A short hairpin RNA (shRNA) from Open Biosystems
(Thermo Fisher Scientiﬁc). Two different CLEC16A shRNA
were used: #1, CAGCTCTGTATTTGACTTCTT; and #2,
GCTAAGACTGAACAGGATATT. For lentivirus production,
we transfected HEK293T cells with packaging constructs
(pRSV-Rev, pCMV-VSV-G and pMDLg/pRRE) and shRNA
using polyethylenimine (PEI, MW 25kDa, Polysciences). In
each experiment, cotransfection with a pEGFP-C1 construct
revealed 70–80% GFP+ cells. After 2–3 days of cell culture,
the supernatants were ﬁltered and lentivirus was concentrated
using ultracentrifugation. Viral particles were taken up in
medium, snap-frozen and stored at 80C.
Thawed monocytes were transduced with lentivirus in
CellGro serum-free medium (CellGenix) supplemented with
polybrene (4mg/ml) and cultured in the presence of IL4
(800U/ml) and GM-CSF (1000U/ml) for differentiation into
dendritic cells. Dendritic cells were split 6 days after transduc-
tion and one part was matured by addition of LPS (1 mg/ml)
and IFNG (1000U/ml) for 24 h. Dendritic cell differentiation
and maturation was determined by ﬂow cytometric analysis of
CD11c, HLA-DR, CD40, CD80, CD83 and CD86 expression.
Co-immunoprecipitation and
immunoblotting
HEK293T cells transfected with HA- and GFP-tagged
CLEC16A, RILP and/or HOPS complex proteins were lysed
for 30min in 0.8% NP-40 lysis buffer containing 50mM
NaCl, 50mM Tris-HCl, 10mM MgCl2 and a protease inhibi-
tor cocktail (EDTA-free; Roche Applied Science). After spin-
ning (15min at 14 000g), the supernatants were incubated
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with anti-HA or -GFP antibodies coupled to Protein
G-Sepharose 4 Fast Flow beads (GE Healthcare) for 1 h.
Beads were washed in 8% NP-40 lysis buffer and three
times in 0.08% NP-40 buffer containing 50mM Tris-HCl,
500mM NaCl and 5mM MgCl2 before adding sample
buffer and incubation for 5min at 95C. Immune-precipitated
proteins were detected via sodium dodecyl sulphate polyacryl-
amide gel electrophoresis followed by immunoblotting on
polyvinylidene diﬂuoride membranes for 2 h at 300 mA at
4C. Membranes were probed with an HRP-conjugated rat
anti-HA (Roche Applied Science) or rabbit anti-GFP (Rocha
et al., 2009) antibody. Protein bands were visualized using
ECL (Supersignal West Dura Extended Duration Substrate;
Thermo Fisher Scientiﬁc).
Electron microscopy
Either peripheral blood mononuclear cells containing around
40% of monocytes or stable MelJuSo CLEC16A or scrambled
shRNA transductants were ﬁxed for 2 h in a mixture of 2%
paraformaldehyde and 0.2% glutaraldehyde in 60mM PIPES,
25mM HEPES, 2mM MgCl2, 10mM EGTA, pH 6.9 and
further processed for ultrathin cryosectioning as described
(Calafat et al., 1997). For immunolabelling, the sections were
incubated for 10min with 0.15M glycine in PBS and for
10min with 1% bovine serum albumin (BSA) in PBS to
block free aldehyde groups and prevent aspeciﬁc antibody
binding, respectively. Sections were incubated with either
rabbit anti-CLEC16A antibody (Sigma-Aldrich) followed by
swine anti-rabbit IgG as a signal strengthening step or with
rabbit anti-HLA-II antibody (made by J. Neefjes) and 10 nm
protein-A conjugated colloidal gold (EM Lab, University of
Utrecht, The Netherlands), all in 1% BSA in PBS. Finally,
the cryosections were embedded in uranylacetate and methyl-
cellulose and assessed by a Philips CM 10 electron microscope
(FEI).
For electron microscopy quantiﬁcation, internal vesicle-poor
multivesicular bodies were deﬁned as late endosomal compart-
ments containing 550% of internal vesicles. Only HLA-II +
multivesicular bodies were analysed. Each electron microscopy
image represented a 70 nm section of a single cell, in which the
number of HLA-II molecules was related to that of multivesi-
cular bodies to calculate the relative number of HLA-II per
multivesicular body. Multivesicular body and HLA-II numbers
were counted in triplicate in 12–15 different cells and were
conﬁrmed by a second independent observer.
Fluorescence microscopy and
imaging analysis
We used a ﬂuorescence (Zeiss Axioplan 2) and confocal laser-
scanning (Leica TCS SP2) microscope together with Leica LAS
AF and ImageJ software to analyse cells. To quantify
co-localization, we calculated the Pearson’s correlation coefﬁ-
cient for each cell using the co-localization tool in LAS AF.
Co-localization analysis was done on representative images.
For the quantiﬁcation of late endosome localization, ﬁrst the
outermost cytoplasmic region of each cell was determined
using HLA-DR as plasma membrane marker. Then, a line
scan was performed by taking the shortest distance from the
nuclear rim (DAPI+ ) to this area. Finally, ﬂuorescence
intensities for each line region of interest were assessed using
the line proﬁle tool in LAS AF.
Brain lesion staging
Staging of multiple sclerosis lesions in brain white matter tissue
was performed as previously reported (van der Valk and De
Groot, 2000). In short, lesions were characterized using Oil
Red O to detect myelin degradation products and monoclonal
antibodies against HLA-II and PLP or MOG. Lesion stages
included normal-appearing white matter as well as pre-active,
active demyelinating, chronic active and chronic inactive
lesions.
Statistical analysis
Statistical analyses were performed in SPSS 20.0 and
GraphPad Prism, version 5.04 software. The two-tailed
Mann-Whitney U-test was used to compare two groups. For
comparison of more than two groups, we performed the
Kruskal-Wallis followed by the Dunn’s multiple comparison
test. Correlations were evaluated using Spearman’s rank test
or linear regression analysis. P-values5 0.05 were considered
as statistically different. Mean values and standard errors of
the mean are indicated, unless stated otherwise.
Results
CLEC16A is abundant in monocytic
cells and monocyte-derived dendritic
cells and localizes with HLA class II
We ﬁrst assessed CLEC16A expression levels in selected
peripheral blood leukocyte subsets of healthy donors
(n = 3–4). CLEC16A protein expression was low in T
cells, moderate in natural killer and B cells and highest in
monocytes (Fig. 1A and Supplementary Fig. 1A), consistent
with the reported mRNA expression levels of CLEC16A
for these subsets (Gene Expression Atlas; www.ebi.ac.uk/
gxa). In primary monocytes (n = 2), CLEC16A was mainly
seen on vesicular membranes near the nuclear indentation
(Fig. 1B and Supplementary Fig. 1B). CLEC16A levels were
not altered in monocyte-derived macrophages
(Supplementary Fig. 1C), but were 2-fold higher in mono-
cyte-derived dendritic cells than in the monocytes from the
same donor (Fig. 1C and Supplementary Fig. 1D, n = 7).
We obtained comparable results after lipopolysaccharide-
induced maturation of macrophages (Supplementary Fig.
1C) and monocyte-derived dendritic cells (Fig. 1C and
Supplementary Fig. 1D and E, n = 7).
Interestingly, in monocyte-derived dendritic cells, mRNA
expression levels of CLEC16A strongly correlated with
those of its neighbouring gene, CIITA (r = 0.87,
P = 0.005; Fig. 1D, n = 9). This was also found for
CLEC16A and HLA-DRA mRNA levels (Supplementary
Fig. 1F), suggesting coordinate expression of CLEC16A
and HLA-II. Immunoﬂuorescence assessment of immature
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monocyte-derived dendritic cells (n = 3) showed partial co-
localization of CLEC16A with HLA-DR, particularly in
perinuclear regions (Pearson’s correlation coefﬁcient = 0.78;
Fig. 1E). LPS-induced maturation of monocyte-derived den-
dritic cells (n = 3) resulted in a shift of CLEC16A and
HLA-DR co-localization towards peripheral regions near
or at the plasma membrane (Pearson’s correlation coefﬁ-
cient = 0.76; Fig. 1E). This co-localization was seen for dif-
ferent monocyte-derived dendritic cells (Supplementary Fig.
2). The strong expression of CLEC16A in primary mono-
cytes and its association with HLA-II in monocyte-derived
dendritic cells suggest a role of CLEC16A in late endoso-
mal processing of HLA-II by antigen-presenting cells.
CLEC16A knockdown impairs the
biogenesis of HLA class II-positive
late endosomal compartments
Drosophila mutants of CLEC16A orthologue Ema fail to
form mature late endosomes and lysosomes (Kim et al.,
2010). Additionally, several signalling motifs targeting
Figure 1 CLEC16A is abundant in monocytes and monocyte-derived cells from peripheral blood of healthy donors. (A) Flow
cytometric analysis of total CLEC16A expression levels in peripheral blood mononuclear cells (PBMC) of four healthy individuals (age/gender: 54/F,
48/M, 28/M, 56/F). Cells were stained with monoclonal antibodies against CD3, CD19, CD56 or CD14 and CLEC16A to evaluate CLEC16A mean
fluorescence intensity in T, B and NK cells and monocytes (P = 0.0049, Kruskal-Wallis test). (B) Vesicular localization of CLEC16A around the
nuclear indentation of monocytes from buffy coats, as determined by immunogold-labelling of rabbit anti-CLEC16A antibody and electron
microscopy. This was observed for monocytes from two different donors. Scale bar = 500 nm. (C) Relative CLEC16A mRNA expression levels in
monocytes and both unstimulated and LPS-stimulated monocyte-derived dendritic cells (moDC) of the same healthy donors (n = 7). (D)
Correlation between CLEC16A and CIITA mRNA expression levels in immature monocyte-derived dendritic cells from similar donors (n = 9).
(E) Representative immunofluorescence co-staining for CLEC16A and HLA-DR in immature and mature monocyte-derived dendritic cells, as
analysed by confocal microscopy. Rabbit anti-CLEC16A and mouse anti-HLA-DR (L243 clone) antibodies were used. Scale bars = 10 mm.
*P5 0.05; **P5 0.01.
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antigens to HLA-II + late endosomal compartments or
MIIC (Mahnke et al., 2000) are present in CLEC16A
(e.g. EDE triads; see Supplementary Fig. 3). To explore a
role for CLEC16A in the HLA-II antigen presentation path-
way in human antigen-presenting cells, we ﬁrst used the
melanoma MelJuSo cell line, which is a frequently used
antigen-presenting cell model to study late endosomal and
HLA-II biology (Wubbolts et al., 1996). CLEC16A siRNA
transfections caused a 59–72% reduction in CLEC16A
mRNA levels compared to scrambled siRNA (Fig. 2A).
When analysing late endosomal distribution, both CD63+
and HLA-DR+ late endosomes were strongly dispersed in
CLEC16A siRNA-treated cells, in contrast to the peri-
nuclear localization in controls (Fig. 2B–D). These observa-
tions were made using several duplexes of CLEC16A
siRNA (Supplementary Fig. 4A) and conﬁrmed by assessing
another late endosomal marker, Rab7, in co-localization
with HLA-DR in Rab7-GFP+ MelJuSo cells (Supplemen-
tary Fig. 4B). The late endosomal scattering was reversed
after re-expression of CLEC16A (Supplementary Fig. 5A
and B). These observations provide strong evidence that
CLEC16A silencing disrupts late endosomal biogenesis.
To verify these ﬁndings, we generated stable MelJuSo
transductants containing scrambled or CLEC16A shRNA.
CLEC16A mRNA expression levels were markedly
decreased in CLEC16A shRNA transductants (mean reduc-
tion of 74%), whereas both CIITA and HLA-DRA mRNA
levels remained unaffected (Fig. 3A). Electron microscopy
revealed multivesicular bodies that completely lacked in-
ternal vesicles or consisted of a few remaining internal ves-
icles with an enlarged phenotype in CLEC16A shRNA
transductants (Fig. 3B), indicating abnormal maturation
of late endosomes. Three-fold more internal vesicle-poor
than internal vesicle-rich multivesicular bodies were found
(Fig. 3C). In addition, the number of HLA-II molecules in
multivesicular bodies of CLEC16A shRNA transductants
were increased 3-fold (Fig. 3B and D), without affecting
multivesicular body size (Supplementary Fig. 5C).
Together, this suggests that CLEC16A has an important
role in the cytoplasmic localization and formation of
MIIC, thereby regulating HLA-II expression in antigen-
presenting cells.
Silencing of CLEC16A leads to
intracellular accumulation and
reduced plasma membrane
expression of HLA class II
In CLEC16A siRNA-treated MelJuSo cells, HLA-DR sur-
face expression was reduced by 16–25% compared to con-
trols (Fig. 4A). HLA-DRA mRNA expression levels were
not reduced after CLEC16A siRNA transfection
(Supplementary Fig. 5D), demonstrating that the reduction
of HLA-DR surface levels by CLEC16A siRNA is inde-
pendent of HLA-DR transcription. Simultaneous transfec-
tions with siRNA duplexes against HLA-DMb caused a
2-fold upregulation of class II-associated invariant chain
peptide (CLIP) surface expression (Supplementary Fig.
5E), which conﬁrmed the efﬁcacy of siRNA transfection.
In addition, several foci of HLA-DR+ late endosomes
were seen after CLEC16A siRNA treatment (Fig. 2B and
Supplementary Fig. 4). This is consistent with the reduced
HLA-DR cell surface expression (Fig. 4A), and the accu-
mulation of HLA-II in multivesicular bodies as observed by
electron microscopy (Fig. 3B and D) in MelJuSo cells.
To substantiate this in primary antigen-presenting cells,
CLEC16A expression was silenced in monocyte-derived
dendritic cells using CLEC16A shRNA lentivirus
(Supplementary Fig. 6A). In line with MelJuSo cells, imma-
ture and mature monocyte-derived dendritic cells showed a
reduced HLA-DR surface expression (mean reduction of
20–38%; Fig. 4B, n = 3–5). In parallel, intracellular analysis
revealed several foci of HLA-DR+ late endosomes in im-
mature monocyte-derived dendritic cells (Fig. 4C and
Supplementary Fig. 6B and C) and a more immature
HLA-DR phenotype for maturation-induced monocyte-
derived dendritic cells (Fig. 4D and Supplementary Fig.
6D and E) after transduction with CLEC16A shRNA. In
conclusion, CLEC16A regulates intracellular and surface
expression of HLA-DR also in primary antigen-presenting
cells, likely by controlling the biogenesis of HLA-II + late
endosomes (Figs 2 and 3).
CLEC16A is directly involved in
RILP-mediated recruitment of late
endosomes to regulate HLA class II
In Drosophila, Ema directly interacts with the HOPS com-
plex (Kim et al., 2010), a Rab7-activating complex consist-
ing of different vacuolar protein sorting subunits that play
a critical role in late endosomal biogenesis in yeast (Rink
et al., 2005; Plemel et al., 2011). RILP also binds to the
HOPS and dynein motor complex to transport Rab7+ late
endosomes along microtubuli to the perinuclear microtu-
bule-organizing centre (Jordens et al., 2001; van der Kant
et al., 2013; Lin et al., 2014). As MIICs are localized dir-
ectly around the microtubule-organizing centre (Wubbolts
et al., 1999), we explored whether CLEC16A is involved in
this late endosomal machinery to control HLA-II
processing.
In CLEC16A-GFP treated MelJuSo cells, a large part of
GFP+ vesicles co-localized with HLA-DR in perinuclear
areas (Supplementary Fig. 7A). HLA-DR was further re-
cruited to these regions after RILP-GFP transfection
(Supplementary Fig. 7B). Cotransfections of MelJuSo cells
with CLEC16A-GFP and RILP-RFP revealed recruitment of
both CLEC16A and HLA-DR to the same perinuclear
region as RILP (Fig. 5A and Supplementary Fig. 7C).
This probably reﬂects the recruitment of HLA-DR+
CLEC16A+ late endosomes to the microtubule-organizing
centre by RILP.
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Next, we performed co-immunoprecipitation assays using
cotransfected HEK293T cells to explore the association of
CLEC16A with molecules of the late endosomal processing
machinery. In pull-down reactions, CLEC16A-GFP
associated with RILP-and VPS41-HA (Fig. 5B and C).
Both RILP and VPS41 did not interact with GFP alone,
conﬁrming the speciﬁcity of all co-immunoprecipitations.
The analyses of total lysates derived from cotransfectants
Figure 2 CLEC16A knockdown in antigen-presenting cells causes dispersed localization of HLA-II-positive late endosomes.
The human melanoma cell line MelJuSo was transfected with three distinct CLEC16A siRNA duplexes (#1, #2 and #3) and analysed after 3 days.
(A) Relative CLEC16A mRNA levels in CLEC16A siRNA- compared to scrambled siRNA-treated cells (n = 9–17). Cells were also transfected with a
pool of irrelevant HLA-DMb siRNA as additional control. Immunofluorescence analysis (B) and quantification of the cytoplasmic localization of
CD63 + HLA-DR + late endosomes (C and D) in CLEC16A siRNA- and scrambled siRNA-treated MelJuSo cells (n = 17–21). The images are
representative of five experiments. Late endosomal scattering was quantified by analysing fluorescence intensities from the perinuclear area to the
outermost peripheral regions (415mm from the nucleus; 15mm cut-off based on scrambled siRNA histograms) for each cell using a line scan
(LAS AF software). Scale bars = 5mm. ****P5 0.0001.
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showed a similar or higher expression of control GFP-only
relative to CLEC16A-GFP (Fig. 5B and C).
To assess a functional role of CLEC16A in this machin-
ery, we silenced CLEC16A expression and assessed the
perinuclear accumulation of HLA-DR+ late endosomes
mediated by RILP. After transfection with RILP-GFP, peri-
nuclear localization of HLA-DR was markedly disturbed in
CLEC16A siRNA-treated MelJuSo cells. Perinuclear foci of
HLA-DR were elongated instead of round-shaped, in co-
localization with RILP and CD63 (Fig. 5D and
Supplementary Fig. 7D). Additional HLA-DR+CD63+
loci were found in other areas, of which the enlarged
ones were positive for RILP (Fig. 5D and Supplementary
Fig. 7E). HLA-DR surface expression decreased up to 16%
in RILP-GFP+ as compared to GFP cells treated with
scrambled siRNA (Fig. 5E). This effect was abolished by
CLEC16A silencing, since HLA-DR surface expression was
not more reduced in RILP-GFP+ than in GFP cells treated
with CLEC16A siRNA (Fig. 5E). CLEC16A, CIITA and
HLA-DRA mRNA levels were not altered by RILP upre-
gulation (Supplementary Fig. 7F).
This reveals that CLEC16A is essential for the molecular
machinery regulating the trafﬁcking of HLA-II + late endo-
somes. We argue that CLEC16A knockdown impairs late
Figure 3 CLEC16A-silenced antigen-presenting cells contain abnormally matured late endosomes with elevated numbers of
HLA-II. (A) Stable MelJuSo transductants with scrambled shRNA or CLEC16A shRNA were analysed for CLEC16A, CIITA and HLA-DRA mRNA
levels by quantitative PCR (n = 6). In these cells, characteristic features of HLA-II+ late endosomes were assessed using electron microscopy (B).
Both internal vesicle (IV)-poor and -rich multivesicular bodies (MVB) (C) and gold-labelled HLA-II molecules per MVB (D) were quantified. An
asterisk is depicted in the centre of each multivesicular body and arrows indicate abnormally enlarged multivesicular bodies. Scale bars = 250 nm.
**P5 0.01; ***P5 0.001; ****P5 0.0001.
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endosomal transport to perinuclear regions, thereby affect-
ing MIIC formation and HLA-II processing and subsequent
expression at the plasma membrane.
Vitamin D down-modulates CLEC16A
and HLA class II expression in
monocyte-derived dendritic cells
Interestingly, expression of the strongest genetic risk factor
in multiple sclerosis, HLA-DRB1*1501, is modulated by
vitamin D (Ramagopalan et al., 2009b), of which high
serum levels associate with reduced multiple sclerosis risk
(Munger et al., 2006). As vitamin D is able to limit the
antigen presentation capacity of antigen-presenting cells
(Penna et al., 2007; Mora et al., 2008), we explored
whether vitamin D modulates CLEC16A expression in par-
allel with HLA-II in primary antigen-presenting cells.
We cultured monocytes from healthy individuals with the
active form of vitamin D (1,25[OH]2D) during differenti-
ation into monocyte-derived dendritic cells. CLEC16A
mRNA expression levels were signiﬁcantly reduced in
Figure 4 CLEC16A silencing disrupts both intracellular and surface expression of HLA-II in antigen-presenting cells. Relative
cell surface expression levels of HLA-DR for (A) CLEC16A siRNA-treated MelJuSo cells (n = 6–13) as well as (B) CLEC16A shRNA-treated
immature (imDC; n = 4–5) and mature (mDC; n = 3–4) monocyte-derived dendritic cells compared to scrambled controls, as determined by flow
cytometry. (C and D) Intracellular distribution of late endosomes in scrambled and CLEC16A shRNA-treated (C) immature monocyte-derived
dendritic cells (mouse anti-CD63 and rabbit anti-HLA-DR antibody) and (D) mature monocyte-derived dendritic cells (mouse anti-HLA-DR L243
antibody), as analysed by confocal microscopy. Images are representative for three different donors. Scale bars = 10 mm. *P5 0.05; **P5 0.01;
****P5 0.0001.
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vitamin D-treated as compared to untreated monocyte-
derived dendritic cells (Fig. 6A, n = 4). These differences
positively correlated with CIITA mRNA and HLA-DR sur-
face expression levels in monocyte-derived dendritic cells
(Fig. 6B, n = 4–6). Vitamin D stimulation of immature
monocyte-derived dendritic cells did not affect the peri-
nuclear localization of CLEC16A and HLA-DR (data not
shown). Vitamin D treatment of monocyte-derived
Figure 5 CLEC16A is required for RILP-mediated perinuclear recruitment of HLA-II-positive late endosomes. (A) MelJuSo cells
transfected with CLEC16A-GFP and RILP-RFP constructs were assessed for intracellular localization with HLA-DR by confocal microscopy.
(B and C) GFP coimmunoprecipitations of HEK293T cells cotransfected with CLEC16A-GFP and (B) RILP-HA or (C) VPS41-HA constructs. GFP
pull-downs were analysed for HA expression on immunoblots. Immunoprecipitated empty GFP (‘GFP’) constructs served as negative controls.
These data are representative for 2–3 experiments. (D and E) MelJuSo cells treated with scrambled or CLEC16A siRNA were transfected
with a RILP-GFP construct. (D) Intracellular localization (n = 3) and (E) surface expression (n = 3) of HLA-DR was evaluated in RILP-GFP + and
GFP cells 3 days after siRNA transfection [RILP-GFP + versus GFP scrambled siRNA-treated cells (scr): P = 0.06]. Scale bars = 5 mm.
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dendritic cells did impair maturation-induced relocalization
of both CLEC16A and HLA-DR towards peripheral
areas and the plasma membrane (Fig. 6C; representative
for three different donors). These ﬁndings show that
one of the prime environmental factors in multiple sclerosis,
vitamin D, strongly attenuates co-expression of
CLEC16A and HLA-II in monocyte-derived dendritic
cells, which is consistent with the presence of a vitamin
D receptor binding site in their genes (Ramagopalan
et al., 2010).
Figure 6 CLEC16A and HLA-II are co-regulated by vitamin D in monocyte-derived dendritic cells. (A) Quantitative PCR to
determine CLEC16A mRNA expression levels in unstimulated monocyte-derived dendritic cells and monocyte-derived dendritic cells stimulated
with the active form of vitamin D (1,25[OH]2D). Treated and untreated monocyte-derived dendritic cells were analysed 7 days after monocyte
differentiation. (B) CIITA mRNA and HLA-DR cell surface expression levels in untreated compared to vitamin D-treated monocyte-derived
dendritic cells (moDC), as determined by quantitative PCR and flow cytometry, respectively. (C) Representative confocal image showing the
localization of CLEC16A and HLA-DR in untreated and vitamin D-treated monocyte-derived dendritic cells after LPS treatment. The white
dashed line represents the plasma membrane. The images are representative for three different donors and at least 20 monocyte-derived
dendritic cells per donor were analysed. Scale bars = 10mm. *P5 0.05; **P5 0.01.
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CLEC16A expression is elevated in
multiple sclerosis patients and
localizes with HLA class II
To determine whether this novel mechanism of CLEC16A
plays a role in autoimmune disease, we compared
CLEC16A expression in primary cells and tissue between
multiple sclerosis patients and control subjects.
We ﬁrst assessed CLEC16A expression levels in periph-
eral blood mononuclear cells from multiple sclerosis pa-
tients (n = 69) and healthy controls (n = 46;
Supplementary Table 1). A 2-fold increase in CLEC16A
mRNA expression was found for multiple sclerosis patients
as compared to healthy controls (P = 0.003; Fig. 7A). The
expression levels in multiple sclerosis patients did not sig-
niﬁcantly change after correcting for age and gender
(P = 0.26 and P = 0.45, respectively; Supplementary Fig.
8A and B). In healthy controls, we found no association
with gender (P = 0.09) and a biologically irrelevant correl-
ation with age (R2 = 0.11, P = 0.03; Supplementary Fig. 8A
and B), which was abrogated when corrected for gender
(adjusted R2 = 0.09, P = 0.05; data not shown). After cor-
rection for treatment, CLEC16A mRNA levels remained
signiﬁcantly increased in multiple sclerosis patients com-
pared to controls (P = 0.03; Supplementary Fig. 8C).
Stratiﬁcation according to multiple sclerosis risk SNP
rs7200786[A] (Sawcer et al., 2011) did not affect
CLEC16A mRNA levels in multiple sclerosis patients and
healthy controls (P40.09; Supplementary Fig. 8D). When
comparing these levels to monocyte, B cell and both CD4+
and CD8+ T cell frequencies in blood, only a weak correl-
ation was found with CD4+ T cells in multiple sclerosis
(R2 = 0.09, P = 0.02; Supplementary Fig. 9).
In white matter tissue,CLEC16AmRNA levels were 4-fold
elevated in multiple sclerosis cases (n = 14) compared to non-
demented controls (n = 11, Supplementary Table 1; P = 0.03;
Fig. 7B). Additionally, immunohistochemistry for CLEC16A
and HLA-II in white matter tissue from 18 patients with mul-
tiple sclerosis revealed increased frequencies of CLEC16A-
positive cells in pre-active lesions (n = 12), primarily in peri-
vascular lymphocytic inﬁltrates (n = 9), in contrast tomultiple
sclerosis normal-appearing and non-demented control white
matter (n = 17 and n = 9, respectively; Fig. 7C and D).
Multiple sclerosis white matter regions that were strongly
positive for CLEC16A also had high expression of HLA-II
(Fig. 7E). This expression did not always correlate with
CLEC16A, since HLA-II was also present in some
CLEC16A-negative regions (Fig. 7E). Subsequent immuno-
ﬂuorescence analysis showed co-expression of CLEC16A
with HLA-DR in multiple sclerosis white matter (Fig. 7F, rep-
resentative for three patients). The increased expression of
CLEC16A in multiple sclerosis patients and its direct role in
the HLA-II pathway strongly suggest that CLEC16A-
mediated regulation of HLA-II antigen presentation is an
underlying mechanism in multiple sclerosis.
Discussion
The majority of novel multiple sclerosis risk genes identiﬁed
in genome-wide association studies are immune-related and
are shared with many other autoimmune diseases
(Zhernakova et al., 2009; Sawcer et al., 2011; Cotsapas
and Haﬂer, 2012). To unravel the contribution of these
novel risk genes in the cascade that leads to autoimmune
demyelination in multiple sclerosis, it is imperative to de-
termine their biological functions. In silico analysis of ﬁnd-
ings from genome-wide association studies in multiple
sclerosis suggested CD4+T helper cell activation and differ-
entiation as the principal pathogenic mechanism (Sawcer
et al., 2011). Recent studies by our group and others
have shown functional alterations of multiple sclerosis
risk genes that are primarily expressed by T cells
(Gregory et al., 2012; Kreft et al., 2012a, b). Here, we
reveal that the expression of CLEC16A, a gene located at
the 16p13 risk locus, is associated with multiple sclerosis
and has a previously unknown role in the HLA-II antigen
presentation pathway.
Knockdown experiments in different antigen-presenting
cells demonstrate a clear role of CLEC16A in the machinery
regulating both the cytoplasmic localization and maturation
of HLA-II+ late endosomal compartments. The localization
of endosomes is critical for the efﬁciency of HLA-II antigen
presentation and is directly associated with their maturation
(Kleijmeer et al., 2001; Huotari and Helenius, 2011). During
maturation, HLA-II+ late endosomes are transported to peri-
nuclear areas to undergo acidiﬁcation, activating proteolytic
enzymes that process antigens for peptide loading onto
HLA-II molecules (Rocha and Neefjes, 2008). This endoso-
mal maturation and transport to perinuclear regions is
controlled by the dynein motor complex, which forms a
bridge between the microtubuli and Rab7+ late endosomes
(Huotari and Helenius, 2011). The association of CLEC16A
with two main regulators of this machinery, RILP and
HOPS (Fig. 5), suggests that CLEC16A uses this mechanism
to control HLA-II antigen presentation via the MIIC.
This is supported by our recent identiﬁcation of RILP as
a molecule that controls CLIP surface expression (Paul
et al., 2011).
This novel function of CLEC16A is different from that of
other types of C-type lectins. For instance, CLEC9A sup-
ports the cross-presentation to CD8+ T cells, but does not
inﬂuence classical MHC-II antigen presentation in mice
(Zelenay et al., 2012). By contrast, CLECL1, which is
localized at another multiple sclerosis risk locus (Sawcer
et al., 2011), functions as a cell surface receptor to increase
HLA-II expression in dendritic cells (Ryan et al., 2009).
DC-SIGN and DEC-205 also regulate HLA-II antigen pres-
entation by targeting antigens to the MIIC (Mahnke et al.,
2000; Engering et al., 2002). We now demonstrate that
CLEC16A is the ﬁrst member of the C-type lectin family
that controls HLA-II antigen presentation by regulating the
biogenesis of MIIC. As Ema is also associated with
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Figure 7 CLEC16A expression is elevated in peripheral immune cells and brain tissue of multiple sclerosis patients.
(A) Expression levels of CLEC16A mRNA in peripheral blood mononuclear cells (PBMC) of multiple sclerosis patients (MS; n = 69) and healthy
controls (HC; n = 46). (B) CLEC16A mRNA expression levels in brain white matter tissues of multiple sclerosis (n = 14) and non-demented
controls (NDC; n = 11). (C) Representative image of CLEC16A within a perivascular infiltrate (PVI) of a pre-active multiple sclerosis white matter
lesion. Scale bars = 50mm. (D) Quantification of CLEC16A expression in white matter of non-demented controls and in different regions of
multiple sclerosis white matter. We used established arbitrary immunohistochemical scores defined by the number of positive cells in a particular
area. AL = active lesion; CIL = chronic inactive lesion; PAL = pre-active lesion; PVI = perivascular infiltrate; NA = normal appearing. (E)
Immunohistochemistry scores for HLA-II expression in multiple sclerosis white matter regions with negative, intermediate or high CLEC16A
expression. Each dot represents a separate white matter region and a total of 18 multiple sclerosis patients were assessed. (F)
Immunofluorescence analysis of CLEC16A and HLA-DR in multiple sclerosis white matter tissue using confocal microscopy. Co-expression of
CLEC16A and HLA-DR was observed in three different patients. *P5 0.05, **P5 0.01.
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autophagosome formation in Drosophila (Kim et al.,
2012), CLEC16A may also participate in autophagy to me-
diate HLA-II antigen presentation (Schmid et al., 2007;
Soleimanpour et al., 2014).
In addition to its function, we demonstrate an evident
link of CLEC16A expression with multiple sclerosis patho-
genesis. CLEC16A expression in peripheral blood mononu-
clear cells and white matter, especially in perivascular
lymphocytic inﬁltrates, of multiple sclerosis cases was
strongly elevated (Fig. 7). Conﬂicting results have been re-
ported on the genetic link of the CLEC16A region to mul-
tiple sclerosis. In our study, we did not ﬁnd an association
between CLEC16A mRNA levels in blood and the
rs7200786[A] risk SNP, conﬁrming the ENCODE study
(Bernstein et al., 2012; Boyle et al., 2012, 2014; Xie
et al., 2013). Some studies demonstrate risk genotype ef-
fects on the expression of CLEC16A itself (Mero et al.,
2011; Soleimanpour et al., 2014), whereas others have re-
ported effects on its neighbouring genes, such as DEXI
(Leikfoss et al., 2013; Raj et al., 2014). These ﬁndings in-
dicate that expression related to genotypes is probably cell
type-speciﬁc. For example, the correlation with DEXI is
mainly found in CD4+ T cells (Raj et al., 2014), a cell
type in which CLEC16A expression is low (Fig. 1A and
Supplementary Fig. 1A). In addition, genotype effects on
speciﬁc transcripts of CLEC16A have been found in the
thymus, but not in blood (Mero et al., 2011), indicating
that alternative splicing and thereby potentially gene func-
tion are affected. Another possible underlying mechanism is
the selective regulation of CLEC16A gene expression by
vitamin D (Ramagopalan et al., 2010), which also controls
the expression of the major risk locus in multiple sclerosis,
HLA-DRB1 (Ramagopalan et al., 2009b).
The coupling of CLEC16A to the function of HLA-II
indicates that in addition to genetic studies, functional
evaluation of non-HLA risk genes in similar biological
pathways is another attractive strategy to uncover patho-
genic mechanisms in multiple sclerosis (International
Multiple Sclerosis Genetics Consortium, 2013).
Substantial changes in antigen presentation pathways,
which is a generally under-appreciated mechanism in the
multiple sclerosis ﬁeld, are assumed to mediate presentation
of cryptic peptides (Vanderlugt and Miller, 2002).
The increased expression of CLEC16A in multiple sclerosis
Figure 8 Key role of CLEC16A in antigen-presenting cells and multiple sclerosis. Based on the results of our study, we postulate that
CLEC16A expression is elevated in multiple sclerosis to promote HLA-II antigen presentation by antigen-presenting cells. CLEC16A controls the
HLA-II pathway by participating in the molecular machinery of late endosomal biogenesis, which involves the dynein motor complex. Binding of
CLEC16A to this complex via RILP and HOPS probably triggers the transport of late endosomes (LE) along microtubuli and stimulate their
maturation into specialized antigen-loading compartments, termed MIIC. In these compartments, HLA-II molecules are loaded with peptides for
presentation at the plasma membrane. The small circles depicted in late endosomes and the MIIC represent internal vesicles of multivesicular
bodies. In green, the invariant chain and its cleavage product, CLIP, are indicated, which are crucial for efficient HLA-II transport to late endosomes
and loading with peptides, respectively. MS = multiple sclerosis; MT = microtubuli; MTOC = microtubule-organizing centre; RILP = rab7-
interacting lysosomal protein.
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points to an autoimmune model in which it promotes the
biogenesis of MIIC to affect HLA-II antigen presentation
by antigen-presenting cells (Fig. 8). Such a role of
CLEC16A in HLA-II regulation and multiple sclerosis is
likely restricted to selective antigen-presenting cell subsets,
in particular to dendritic cells rather than B cells (Zouk
et al., 2014). This may then alter T cell responses in the
periphery, e.g. by contributing to impaired T cell quies-
cence in patients with multiple sclerosis (Corvol et al.,
2008). The exact aetiological position of CLEC16A, the
way it affects T cell responses, either in the periphery or
during thymic T cell development, and its role in establish-
ing self-tolerance should be addressed in further studies.
In conclusion, we demonstrate that an autoimmunity-
related gene, CLEC16A, has a novel C-type lection
function by regulating the strongest genetic risk factor in
multiple sclerosis, HLA-II. This study takes a ﬁrst step in
coupling the function of non-HLA susceptibility genes to
elucidate underlying mechanisms of multiple sclerosis
pathogenesis. The identiﬁcation of multiple sclerosis-
associated genes regulating HLA-II function, such as
CLEC16A, supports the development of strategies that
selectively manipulate HLA-II antigen presentation in
antigen-presenting cells (van Kasteren et al., 2014), which
will be applicable for multiple sclerosis and a broad
spectrum of other autoimmune diseases.
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